In prostate cancer, knockdown of CD147 or CD44 reduces MCT4 and MRP2 expression, suppresses proliferation and invasion, and increases docetaxel sensitivity in vitro and in vivo (124). This evidence concerns the gene BSG and prostate carcinoma.